Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RLYB | S-4 | neutral | 6/10 | Rallybio Corp (RLYB) filed an S-4 registration statement for a proposed reverse merger with private biotech Avenzo Thera | Jul 15, 2026 |
| CNTN | 3 | neutral | 2/10 | Pamela L. Carter filed a Form 3 initial statement of beneficial ownership with the SEC, reporting zero shares of Canton | Jul 15, 2026 |
| LLY | COURT-RULING | neutral | 2/10 | A magistrate judge in the Northern District of California granted in part and denied in part a discovery motion in Eli L | Jul 15, 2026 |
| QDEL | 3 | neutral | 2/10 | Micah Young, the new Chief Financial Officer of QuidelOrtho Corp, filed a Form 3 initial statement of beneficial ownersh | Jul 15, 2026 |
| CNTN | 3 | neutral | 2/10 | Sean Galvin filed an initial statement of beneficial ownership (Form 3) for Canton Strategic Holdings, Inc. (CNTN), repo | Jul 15, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$8.7M in open-market shares after exercising options, and Director Jan Malcolm sold $179K, t | Jul 15, 2026 |
| CBIO | 8-K, 424B5 | bearish | 6/10 | Crescent Biopharma priced an underwritten public offering of 8,094,793 ordinary shares at $14.50 per share and 525,897 p | Jul 15, 2026 |
| TLX | PRESS-RELEASE | neutral | 4/10 | Telix Pharmaceuticals announced first patient dosing in the Phase 2 OPTIMAL-e trial evaluating TLX597-Tx for metastatic | Jul 15, 2026 |
| BHST | 6-K | neutral | 4/10 | BioHarvest Sciences announced a $1.4M non-dilutive grant from the Israel Innovation Authority to fund an AI-driven R&D i | Jul 15, 2026 |
| EPRX | 6-K | neutral | 2/10 | Eupraxia Pharmaceuticals announced executive leadership changes and an operational restructuring, including the appointm | Jul 15, 2026 |
| CPRX | 25-NSE | bearish | 9/10 | Nasdaq filed a Form 25-NSE to delist Catalyst Pharmaceuticals' common stock under Rule 12d2-2(a)(3), effective immediate | Jul 15, 2026 |
| RDY | 6-K | bearish | 6/10 | Dr. Reddy's disclosed a manufacturing impurity issue in the scale-up of its semaglutide injection API, causing a halt in | Jul 15, 2026 |
| NCEL | 6-K | bullish | 5/10 | NewcelX announced a Brazilian patent grant for its lead T1D cell therapy candidate NCEL-101, extending manufacturing-pro | Jul 15, 2026 |
| PRFX | 6-K | neutral | 3/10 | PRF Technologies (PRFX) announced the expansion of its DeepSolar Predict platform with a new Battery-to-Revenue Intellig | Jul 15, 2026 |
| NUVL | 25-NSE | neutral | 3/10 | Nasdaq filed a 25-NSE notification to delist Nuvalent, Inc. shares following the completion of GSK plc's acquisition. Th | Jul 15, 2026 |
| NTHI | 8-K | neutral | 3/10 | NeOnc Technologies received written FDA feedback on the CMC development program for NEO212, its temozolomide-perillyl al | Jul 15, 2026 |
| GSK | 6-K | bullish | 7/10 | GSK completed its $10.6B acquisition of Nuvalent, adding three lung cancer assets (zidesamtinib, neladalkib, NVL-330) wi | Jul 15, 2026 |
| LEGN | 6-K | bullish | 5/10 | Legend Biotech announced preliminary Q2 2026 CARVYKTI net trade sales of approximately $657M, a strong figure that under | Jul 15, 2026 |
| KAPA | 8-K | neutral | 4/10 | Kairos Pharma announced interim safety data from its Phase 1 trial of ENV-105 + osimertinib in EGFR-mutated NSCLC, repor | Jul 15, 2026 |
| GEVO | 8-K | neutral | 4/10 | Gevo issued a business update highlighting progress on carbon monetization, production expansion, and cost improvements. | Jul 15, 2026 |
| MANE | 8-K | bullish | 6/10 | Veradermics announced positive Phase 2 topline results for VDPHL01 in female pattern hair loss, showing mean TAHC increa | Jul 15, 2026 |
| NUVL | 8-K | bullish | 5/10 | GSK plc has completed its acquisition of Nuvalent, Inc. via a tender offer and merger. The tender offer expired with 91. | Jul 15, 2026 |
| SPRC | PRESS-RELEASE | bullish | 5/10 | SciSparc subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site at Hannover Medical School for SCI-110, a | Jul 15, 2026 |
| GMAB | 6-K | neutral | 3/10 | Genmab disclosed Q2 2026 worldwide net sales of DARZALEX at USD 4,207 million, with USD 2,435 million in the U.S. and US | Jul 15, 2026 |
| SNTI | DEFA14A, 8-K | mixed | 7/10 | Senti Biosciences (SNTI) entered into a merger agreement with a Celadon affiliate to spin off its lead asset SENTI-202 i | Jul 15, 2026 |
| RANI | PRESS-RELEASE | bullish | 7/10 | Rani Therapeutics reported positive initial Phase 1a data for RT-114, an oral RaniPill® capsule delivering a GLP-1/GLP-2 | Jul 15, 2026 |
| JNJ | 8-K | bullish | 6/10 | JNJ reported Q2 2026 adjusted EPS of $2.90, a 1.6% beat vs. consensus of $2.85, on revenue of $25.31B (6.6% YoY growth, | Jul 15, 2026 |
| CASIF | 6-K | bullish | 7/10 | CASI Pharmaceuticals won a final arbitration award against Juventas, with the tribunal rejecting all of Juventas' claims | Jul 15, 2026 |
| AEON | 424B4 | bearish | 7/10 | AEON Biopharma priced a highly dilutive underwritten offering of 17.85M shares and 24.84M pre-funded warrants (each with | Jul 15, 2026 |
| SVA | 6-K | neutral | 2/10 | Sinovac Biotech announced a further extension of the deadline for shareholders to submit payment instructions for its pr | Jul 15, 2026 |